BibTex RIS Kaynak Göster
Yıl 2015, Cilt: 32 Sayı: 4, 352 - 358, 01.10.2015

Öz

Kaynakça

  • . Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al; World Health Organization; GA(2)LEN; AllerGen. Allergic rhinitis and its impact on asthma. Allergy 2008;63(Suppl 86):8-160. [CrossRef]
  • 2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64. [CrossRef]
  • 3. Leynaert B, Neukirch C, Kony S, Guénégou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol 2004;113:86-93. [CrossRef]
  • 4. Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res 2010;2:65-76. [CrossRef]
  • 5. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006;34:97-115. [CrossRef]
  • 6. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111(Suppl 2):S486-94. [CrossRef]
  • 7. Amin K. The role of mast cells in allergic inflammation. Respir Med 2012;106:9-14. [CrossRef]
  • 8. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-80. [CrossRef]
  • 9. Bradding P. The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 2003;3:45-50. [CrossRef]
  • 10. Lee NA, Gelfand EW, Lee JJ. Pulmonary T cells and eosinophils: conspirators or independent triggers of allergic respiratory pathology? J Allergy Clin Immunol 2001;107:945-57. [CrossRef]
  • 11. Wagenmann M, Schumacher L, Bachert C. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 2005;60:1132-8. [CrossRef]
  • 12. Ohkubo K, Ikeda M, Pawankar R, Gotoh M, Yagi T, Okuda M. Mechanisms of IL-6, IL-8, and GM-CSF release in nasal secretions of allergic patients after nasal challenge. Rhinology 1998;36:156-61.

In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial

Yıl 2015, Cilt: 32 Sayı: 4, 352 - 358, 01.10.2015

Öz

Background: Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties. Aims: We evaluated the plasma level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after a 4-week treatment with H1 antihistamines, as well as the risk of asthma after 1.5 years. Study Design: Randomized clinical trial. Methods: Eighty-five patients with PAR and 30 healthy volunteers were included in the study. The patients with PAR were randomly divided into 2 groups: 41 patients treated with 5 mg/day desloratadine and 44 patients under 5 mg/day levocetirizine for 4 weeks. The clinical and biological evaluations were performed before and after treatment and included rhinitis symptoms and total symptoms score, type of sensitization, and plasmatic levels of total IgE, IL-1β, IL-6, IL-8 and TNF-α. Results: IL-8 and TNF-α were significantly increased in patients with PAR compared to healthy volunteers (5.85 vs 3.12, p<0.001 and 2.32 vs 1.06, p<0.001, respectively). Both H1 antihistamines reduce all symptoms of allergic rhinitis, including nasal congestion and the plasmatic level of IL-1β, IL-6, IL-8 and TNF-α, after 4 weeks of treatment. The reduction of cytokine levels was not influenced by patients’ age, sex, duration or severity of rhinitis, or type of sensitization. Levocetirizine has a superior effect compared to desloratadine in reducing the rhinitis symptoms and cytokines’ level. Twenty eight (32.9%) of the patients presented asthma symptoms after 1.5 years. The occurrence of asthma was influenced by house dust sensitization (OR-14.6; CI 95% 1.8-116.3; p=0.01), but baseline values of cytokines were not predictive factors for its appearance. Conclusion: Levocetirizine and desloratadine as a prolonged therapy reduce plasmatic levels of some pro-inflammatory cytokines in patients with PAR. Levocetirizine has a better effect on decreasing the symptoms and plasmatic levels of IL-1β and IL-8. (ClinicalTrials.gov Identifier: NCT02507635) Founding: POSDRU and University of Medicine and Pharmacy, Iuliu Haţieganu, Cluj Napoca.

Kaynakça

  • . Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al; World Health Organization; GA(2)LEN; AllerGen. Allergic rhinitis and its impact on asthma. Allergy 2008;63(Suppl 86):8-160. [CrossRef]
  • 2. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64. [CrossRef]
  • 3. Leynaert B, Neukirch C, Kony S, Guénégou A, Bousquet J, Aubier M, et al. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol 2004;113:86-93. [CrossRef]
  • 4. Min YG. The pathophysiology, diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res 2010;2:65-76. [CrossRef]
  • 5. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006;34:97-115. [CrossRef]
  • 6. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111(Suppl 2):S486-94. [CrossRef]
  • 7. Amin K. The role of mast cells in allergic inflammation. Respir Med 2012;106:9-14. [CrossRef]
  • 8. Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994;10:471-80. [CrossRef]
  • 9. Bradding P. The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 2003;3:45-50. [CrossRef]
  • 10. Lee NA, Gelfand EW, Lee JJ. Pulmonary T cells and eosinophils: conspirators or independent triggers of allergic respiratory pathology? J Allergy Clin Immunol 2001;107:945-57. [CrossRef]
  • 11. Wagenmann M, Schumacher L, Bachert C. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. Allergy 2005;60:1132-8. [CrossRef]
  • 12. Ohkubo K, Ikeda M, Pawankar R, Gotoh M, Yagi T, Okuda M. Mechanisms of IL-6, IL-8, and GM-CSF release in nasal secretions of allergic patients after nasal challenge. Rhinology 1998;36:156-61.
Toplam 12 adet kaynakça vardır.

Ayrıntılar

Diğer ID JA46ZP29VU
Bölüm Araştırma Makalesi
Yazarlar

Corina İ. Bocşan Bu kişi benim

Ştefan C. Vesa Bu kişi benim

Adriana İ. Bujor Bu kişi benim

Nicolae Miron Bu kişi benim

Diana Deleanu Bu kişi benim

Anca D. Buzoianu Bu kişi benim

Yayımlanma Tarihi 1 Ekim 2015
Yayımlandığı Sayı Yıl 2015 Cilt: 32 Sayı: 4

Kaynak Göster

APA Bocşan, C. İ., Vesa, Ş. C., Bujor, A. İ., Miron, N., vd. (2015). In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Medical Journal, 32(4), 352-358.
AMA Bocşan Cİ, Vesa ŞC, Bujor Aİ, Miron N, Deleanu D, Buzoianu AD. In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Medical Journal. Ekim 2015;32(4):352-358.
Chicago Bocşan, Corina İ., Ştefan C. Vesa, Adriana İ. Bujor, Nicolae Miron, Diana Deleanu, ve Anca D. Buzoianu. “In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial”. Balkan Medical Journal 32, sy. 4 (Ekim 2015): 352-58.
EndNote Bocşan Cİ, Vesa ŞC, Bujor Aİ, Miron N, Deleanu D, Buzoianu AD (01 Ekim 2015) In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Medical Journal 32 4 352–358.
IEEE C. İ. Bocşan, Ş. C. Vesa, A. İ. Bujor, N. Miron, D. Deleanu, ve A. D. Buzoianu, “In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial”, Balkan Medical Journal, c. 32, sy. 4, ss. 352–358, 2015.
ISNAD Bocşan, Corina İ. vd. “In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial”. Balkan Medical Journal 32/4 (Ekim 2015), 352-358.
JAMA Bocşan Cİ, Vesa ŞC, Bujor Aİ, Miron N, Deleanu D, Buzoianu AD. In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Medical Journal. 2015;32:352–358.
MLA Bocşan, Corina İ. vd. “In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial”. Balkan Medical Journal, c. 32, sy. 4, 2015, ss. 352-8.
Vancouver Bocşan Cİ, Vesa ŞC, Bujor Aİ, Miron N, Deleanu D, Buzoianu AD. In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial. Balkan Medical Journal. 2015;32(4):352-8.